The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions
Author:
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Physiology
Link
http://link.springer.com/content/pdf/10.1007/s10620-017-4479-0.pdf
Reference120 articles.
1. Ritchie J, Powell-Tuck T, Lennard-Jones JE. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet. 1978;311:1140–1143.
2. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666–3670.
3. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985;316:552–554.
4. Simpson SJ, Hollander GA, Mizoguchi E, et al. Expression of pro-inflammatory cytokines by TCR alpha beta + and TCR gamma delta + T cells in an experimental model of colitis. Eur J Immunol. 1997;27:17–25.
5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Vedolizumab (VDZ) for UC and CD: Still Safe and Effective After All These Years;Digestive Diseases and Sciences;2020-03-24
2. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don’t We Know, and What Do We Yearn to Know?;Gastrointestinal Endoscopy Clinics of North America;2019-07
3. Recent advances in the treatment of C. difficile using biotherapeutic agents;Infection and Drug Resistance;2019-06
Recent advances in the treatment of C. difficile using biotherapeutic agents
4. Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De‐Escalation in Adults With Inflammatory Bowel Diseases;Clinical Pharmacology & Therapeutics;2019-04-29
5. Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects;The Journal of Clinical Pharmacology;2019-02-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3